|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, coexpression of Snail and ABCB1 was observed in CRC patients.
|
31774615 |
2020 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overall, our data show that EGCG may be act as a novel chemo-sensitizer, and the GRP78/NF-κB/miR-155-5p/MDR1 pathway plays a vital role in EGCG enhancing the sensitivity of colorectal cancer to 5-FU.
|
30741544 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
P-Glycoprotein 1 Affects Chemoactivities of Resveratrol against Human Colorectal Cancer Cells.
|
31487863 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cellular polarity modulates drug resistance in primary colorectal cancers via orientation of the multidrug resistance protein ABCB1.
|
30306567 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, a panel of 5 SNPs, namely ABCC2 (-24C > T/rs717620 and c.4544 G > A/rs8187710), ABCG2 (c.421 C > A/rs2231142), ABCB1 (c.3435 C > T/rs1045642) and SLC31A1 (c.-36 + 2451 T > G/rs10981694), was evaluated to assess their association with grade 2-3 OXPN in metastatic CRC patients.
|
30713338 |
2019 |
|
Epilepsy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Further, for NF-κB p65, MDR1, P-gp and apoptosis-associated protein levels detection, miR-542-3p mimic showed a suppressive effect on these KA-induced protein levels, whereas TLR4 overexpression ameliorated the miR-542-3p-induced these protein levels in KA-treated epilepsy rats.
|
31702493 |
2019 |
|
Epilepsy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our data provide key signaling steps underlying seizure-induced P-gp up-regulation and suggest that mPGES-1 inhibitors could potentially prevent P-gp up-regulation in epilepsy.-Soldner, E. L. B., Hartz, A. M. S., Akanuma, S.-I., Pekcec, A., Doods, H., Kryscio, R. J., Hosoya, K.-I., Bauer, B. Inhibition of human microsomal PGE2 synthase-1 reduces seizure-induced increases of P-glycoprotein expression and activity at the blood-brain barrier.
|
31638830 |
2019 |
|
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Neuroinflammation due to high levels of glutamate has been identified as one of the causes of P-gp upregulation, and several studies in animal models of epilepsy suggest that antiinflammatory drugs might prevent P-gp overexpression and, thus, avoid the development of refractory epilepsy.
|
31420290 |
2019 |
|
Epilepsy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our data support the hypothesis that glutamate signals cPLA2 activation, resulting in overexpression of blood-brain barrier P-gp and BCRP.-Hartz, A. M. S., Rempe, R. G., Soldner, E. L. B., Pekcec, A., Schlichtiger, J., Kryscio, R., Bauer, B. Cytosolic phospholipase A2 is a key regulator of blood-brain barrier function in epilepsy.
|
31661303 |
2019 |
|
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Increasing evidence supports that the efflux transporters, especially P-glycoprotein (P-gp), have vital roles on drug resistance in epilepsy.
|
31061316 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma.
|
31244936 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This underscores the need for combinatorial approaches with focus on PXR antagonism to improve drug effectiveness in hepatocellular carcinoma.<b>Abbreviations:</b> HCC: Hepatocellular Carcinoma; FDA: Food and Drug Administration; TGF-β: Transforming growth factor-β; PXR: Pregnane X receptor; CAR: Constitutive androstane receptor; P-gp/ABCB1: P-glycoproteins/ATP-binding cassette transporter subfamily B member 1; MRP1/ABCC1 and MRP2/ABCC2: Multidrug-resistance associated proteins; BCRP/ABCG2: Breast cancer resistant protein; DMEs: Drug-metabolizing enzymes; CFDA: 5,6-carboxyfluorescein diacetate; ETS1: Transcription factor E26 transformation specific sequence 1.
|
31739702 |
2019 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MDR1 gene polymorphism correlated with pathological characteristics and prognosis in patients with primary hepatocellular carcinoma receiving interventional therapy.
|
30779721 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results indicate that elevated ABCB1 expression induced by C-terminal truncation of HBx was responsible for doxorubicin resistance in HCC.
|
30982500 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we tested the P-gp interaction of some A<sub>3</sub> adenosine receptor agonists that are being developed for the treatment of chronic diseases, including rheumatoid arthritis, psoriasis, chronic pain, and hepatocellular carcinoma.
|
31127007 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Repression of RNA pol III-dependent transcription by chemical inhibition or knockdown of BRF1 RNA pol III transcription initiation factor subunit (BRF1) enhanced HCC cell sensitivity to doxorubicin, suggesting that MAF1 regulates doxorubicin resistance in HCC by controlling RNA pol III-dependent transcription.
|
31645432 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We used qRT-PCR to measure expressions of miR-122, β-catenin and MDR1 in four HCC cell lines.
|
30539797 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
|
30801960 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings establish a novel miRNA-based approach for autophagy interference to reverse doxorubicin resistance in future chemotherapy regimens against human HCC.
|
31695022 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
N-Acetyltransferase 10 Enhances Doxorubicin Resistance in Human Hepatocellular Carcinoma Cell Lines by Promoting the Epithelial-to-Mesenchymal Transition.
|
31354912 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Consequently, P-gp will play an important role in the disposition of cinobufotalin <i>in vivo</i>, which provided a new combination therapy for the clinical treatment of HCC.
|
31156437 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Further studies on herbal medicines with demonstrated effects against P-gp overexpression will aid in improving the efficacy of chemotherapy in CRC.
|
30158992 |
2018 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
While expression levels of Nrf2 and ABCB1 (P-gp) were markedly higher in both mRNA and protein levels in CRC biopsies (p < 0.01), Keap1 expression level was significantly lower in these samples (p < 0.05).
|
29793178 |
2018 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, studies of colorectal cancer specimens indicated that the expression of miR-26b and Pgp had inverse correlation.
|
30662808 |
2018 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genotyping of ABCB1 variants can help to prevent severe adverse reactions to irinotecan-based treatments in colorectal cancer.
|
30213564 |
2018 |